

# Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells

Magnus A. G. Hoffmann<sup>a</sup>, Yotam Bar-On<sup>b</sup>, Zhi Yang<sup>a</sup>, Harry B. Gristick<sup>a</sup>, Priyanthi N. P. Gnanaprasagam<sup>a</sup>, Jost Vielmetter<sup>a</sup>, Michel C. Nussenzweig<sup>b</sup>, and Pamela J. Bjorkman<sup>a,1</sup>

<sup>a</sup>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125; and <sup>b</sup>Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10065

Contributed by Pamela J. Bjorkman, June 21, 2020 (sent for review May 27, 2020; reviewed by Nathaniel R. Landau and Roland K. Strong)

CD4-based decoy approaches against HIV-1 are attractive options for long-term viral control, but initial designs, including soluble CD4 (sCD4) and CD4-Ig, were ineffective. To evaluate a therapeutic that more accurately mimics HIV-1 target cells compared with monomeric sCD4 and dimeric CD4-Ig, we generated virus-like nanoparticles that present clusters of membrane-associated CD4 (CD4-VLPs) to permit high-avidity binding of trimeric HIV-1 envelope spikes. In neutralization assays, CD4-VLPs were >12,000-fold more potent than sCD4 and CD4-Ig and >100-fold more potent than the broadly neutralizing antibody (bNAb) 3BNC117, with >12,000-fold improvements against strains poorly neutralized by 3BNC117. CD4-VLPs also neutralized patient-derived viral isolates that were resistant to 3BNC117 and other bNAbs. Intraperitoneal injections of CD4-CCR5-VLP produced only subneutralizing plasma concentrations in HIV-1-infected humanized mice but elicited CD4-binding site mutations that reduced viral fitness. All mutant viruses showed reduced sensitivity to sCD4 and CD4-Ig but remained sensitive to neutralization by CD4-VLPs in vitro. In vitro evolution studies demonstrated that CD4-VLPs effectively controlled HIV-1 replication at neutralizing concentrations, and viral escape was not observed. Moreover, CD4-VLPs potently neutralized viral swarms that were completely resistant to CD4-Ig, suggesting that escape pathways that confer resistance against conventional CD4-based inhibitors are ineffective against CD4-VLPs. These findings suggest that therapeutics that mimic HIV-1 target cells could prevent viral escape by exposing a universal vulnerability of HIV-1: the requirement to bind CD4 on a target cell. We propose that therapeutic and delivery strategies that ensure durable bioavailability need to be developed to translate this concept into a clinically feasible functional cure therapy.

HIV-1 | decoy therapeutics | virus-like particles | functional cure

Antiretroviral therapy (ART) prolongs the life expectancy of HIV-1-infected individuals but is associated with side effects, and multiple drugs need to be given in combination to prevent the development of viral resistance (1). In addition, treatment must continue for the lifetime of the individual due to the existence of a long-lived latent proviral reservoir. While a “sterilizing” cure remains difficult to achieve due to difficulties associated with identifying and clearing latently infected cells (2, 3), recent research has focused on designing a “functional” cure, i.e., a therapeutic strategy that enables long-term suppression of HIV-1 replication and remission of symptoms in the absence of ART (4).

The development of viral resistance is a major obstacle to achieving a functional cure, since low levels of latent replication-competent viruses persist in the body. Decoy approaches that closely mimic HIV-1 target cells are attractive options for long-term viral control, as viral resistance through mutation cannot develop without concomitant loss of target cell infectivity (5, 6). HIV-1 primarily infects CD4<sup>+</sup> T cells; the gp120 subunit of the viral envelope glycoprotein (Env) initially binds CD4, triggering

a conformational change that allows it to interact with a host cell coreceptor protein, the chemokine receptor CCR5 or CXCR4, leading to fusion between the viral and host cell membranes (7).

Initial attempts to design decoys against HIV-1 used a soluble form of CD4 (sCD4) to block the receptor-binding sites on Env, but this strategy proved ineffective in patients (8, 9). Subsequent studies revealed that many primary HIV-1 isolates were relatively insensitive to sCD4 neutralization without apparent loss of viral fitness (10). In addition, HIV-1 can develop resistance to CD4-based inhibitors by acquiring mutations in the CD4-binding site (CD4bs) on gp120 that lower its affinity for CD4 (11–13) (Fig. 1). A potential explanation for the shortcomings of sCD4 therapy is that monomeric sCD4 fails to accurately mimic an HIV-1 target cell in which clusters of CD4 molecules on the membrane could enable Env, a trimeric protein with three CD4bs, to form multiple interactions that tether it to the cell surface (14). Thus, HIV-1 variants could escape from sCD4-mediated inhibition through avidity effects that compensate for a lower intrinsic sCD4-binding affinity by using multivalent interactions, thereby retaining the ability to efficiently infect target cells. Dimeric CD4-Ig fusion proteins (CD4-Ig) (15) do not overcome this problem, since bivalent binding with both CD4

## Significance

The ability of HIV-1 to rapidly develop resistance against various therapeutics remains a roadblock to finding a cure. Here we propose that nanoparticle-based therapeutics that mimic HIV-1 target cells by presenting clusters of CD4, the HIV-1 receptor, could prevent effective viral escape. We show that CD4 multimerization on the nanoparticle dramatically enhanced the neutralization potency and breadth compared with conventional CD4-based reagents that present only one or two copies of CD4. The CD4 nanoparticles neutralized a range of diverse HIV-1 strains, including patient isolates resistant to multiple broadly neutralizing antibodies. This work describes a new therapeutic direction that exploits the need of HIV-1 to bind CD4 on target cells, thus warranting further investigation for the potential development of a cure.

Author contributions: M.A.G.H., Y.B.-O., Z.Y., H.B.G., J.V., M.C.N., and P.J.B. designed research; M.A.G.H., Y.B.-O., Z.Y., H.B.G., and P.N.P.G. performed research; M.A.G.H., Y.B.-O., Z.Y., H.B.G., M.C.N., and P.J.B. analyzed data; and M.A.G.H. and P.J.B. wrote the paper.

Reviewers: N.R.L., New York University Langone Medical Center; and R.K.S., Fred Hutchinson Cancer Research Center.


The authors declare no competing interest.

This open access article is distributed under [Creative Commons Attribution License 4.0 \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).

<sup>1</sup>To whom correspondence may be addressed. Email: [bjorkman@caltech.edu](mailto:bjorkman@caltech.edu).

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2010320117/-DCSupplemental>.

First published July 20, 2020.



**Fig. 1.** CD4-VLPs can overcome HIV-1 Env mutations that prevent neutralization by soluble CD4-based inhibitors. Schematic comparison of responses of soluble CD4-based inhibitors and CD4-VLPs to Env mutations. Monovalent sCD4 and bivalent CD4-Ig neutralize sCD4-sensitive strains (purple Env trimers; row 1), but mutations in the CD4bs that lower the affinity of Env for sCD4 (yellow Env trimers; row 2) render other strains resistant to soluble CD4-based inhibitors while maintaining the ability to infect CD4<sup>+</sup> target cells via avidity effects through binding to multiple CD4 receptors tethered to the host cell membrane (row 3). CD4-VLPs can neutralize viral strains that are resistant to soluble CD4-based inhibitors through high-avidity binding to multiple CD4 receptors tethered to the VLP membrane.

arms is prevented by the low density of Env spikes on the viral surface and/or the architecture of single Env trimers (16–18) (Fig. 1).


To test this hypothesis, we generated HIV-1 Gag-based virus-like nanoparticles that present clusters of CD4 in its natural membrane-associated conformation (CD4-VLPs) (Fig. 1). We demonstrate that CD4-VLPs neutralize HIV-1 with enhanced potency and breadth compared with sCD4, CD4-Ig, and 3BNC117, a broadly neutralizing antibody (bNAb) that targets the CD4bs. We also show that viral escape pathways that confer resistance to sCD4 and CD4-Ig are ineffective against CD4-VLPs, suggesting that therapeutics that mimic HIV-1 target cells could prevent viral escape by exposing a universal vulnerability, the requirement to bind clusters of CD4 on a target cell.

## Results

**CD4-VLPs Potently Neutralize HIV-1.** CD4-VLPs were generated by transiently coexpressing HIV-1 Gag and CD4 in Expi293 cells. When expressed in human cells, the Gag polyprotein self-assembles into immature core particles that form ~120-nm-diameter VLPs by budding through the plasma membrane (19). CD4-CCR5-VLPs were also generated to investigate whether adding a coreceptor would enhance the potency and breadth of HIV-1 neutralization. VLPs were collected from transfected cell supernatants and concentrated by centrifugal filtration or sucrose cushion ultracentrifugation (Methods). Western blot analysis confirmed that CD4 and CCR5 were present on CD4-VLPs and CD4-CCR5-VLPs, respectively, but not on control VLPs (Fig. 2A). To determine VLP concentrations, we converted p24 measurements from ELISAs against the Gag p24 capsid protein into VLP concentrations by assuming that each VLP contains 2,000 copies of Gag (20, 21) (Methods). Typical VLP concentrations in transfected supernatants were ~10<sup>10</sup> VLPs/mL, which could be concentrated to ~10<sup>11</sup> VLPs/mL. To estimate the number of CD4 molecules per VLP, we combined supernatants from five independent CD4-VLP productions and purified CD4-VLPs using sucrose cushion ultracentrifugation and size exclusion chromatography (SI Appendix, Fig. S1A and B). Quantitative Western blot analysis showed that purified

CD4-VLPs contained the Gag-EGFP fusion protein and CD4 at a molar ratio of ~14:1 (SI Appendix, Fig. S2A–C), suggesting that CD4-VLPs incorporated an average of 140 ± 48 molecules of CD4. Cryo-electron tomography (cryo-ET) imaging of purified CD4-VLPs revealed spherical particles of ~120 nm diameter with discernible internal layers of immature Gag (Fig. 2B and Movie S1). Although membrane-bound CD4 molecules are too small to be visualized by cryo-ET, their presence on a number of CD4-VLPs, but not on control VLPs, was confirmed by densities for bound soluble Env trimers (Fig. 2B and Movie S1). However, since there is no specific mechanism for packaging CD4 and CCR5 into HIV-1 Gag-based VLPs, CD4-VLPs containing little or no CD4 were also observed.

The ability of CD4-VLPs to inhibit HIV-1 infection of target cells was evaluated using pseudovirus-based TZM-bl neutralization assays (22). CD4-VLPs and CD4-CCR5-VLPs neutralized the HIV-1 strain YU2 at half maximal inhibitory concentrations (IC<sub>50</sub>s) of 0.012 μg p24/mL and 0.006 μg p24/mL, equivalent to 1.5 × 10<sup>8</sup> and 0.8 × 10<sup>8</sup> VLPs/mL, respectively (Fig. 2C). Control VLPs showed no neutralization at concentrations up to 1.5 × 10<sup>10</sup> VLPs/mL. Neutralization activity was independent of the VLP purification method and similar for different batches of CD4-VLPs (SI Appendix, Fig. S3). A concentration of 2.1 × 10<sup>10</sup> CD4 molecules/mL (0.0017 μg/mL) (calculated assuming that each CD4-VLP displays 140 copies of CD4) was required to achieve 50% neutralization. The comparable neutralization profiles of CD4-VLPs and CD4-CCR5-VLPs suggested that the presence of CD4 on VLPs was sufficient for potent HIV-1 neutralization in the absence of CCR5. Extracellular vesicles naturally secreted by eukaryotic cells (23) did not contribute to the neutralization activity of CD4-VLPs, as supernatants from



**Fig. 2.** VLPs incorporate CD4 and CCR5 and neutralize HIV-1. (A) Western blot analysis to detect CD4 (Left) and CCR5 (Right) in supernatants containing HIV-1 Gag-derived VLPs from Expi293 cells transfected with Gag alone (control VLPs; lane 1), Gag and CD4 (CD4-VLPs; lane 2), Gag, CD4, and CCR5 (CD4-CCR5-VLPs; lane 3). (B) Tomographic slices (10.9 nm) from cryo-ET analysis of control VLPs (Left) or CD4-VLPs (Right three panels) incubated with a soluble native-like Env trimer (BG505 SOSIP.664). (Scale bar: 20 nm.) Red arrows indicate densities for bound Env trimers. Approximate positions of immature Gag shell layers are highlighted in the Left two panels. Note the hexagonal lattice in the capsid layer of Gag. See also Movie S1. (C) In vitro neutralization assay against HIV-1<sub>YU2</sub> pseudovirus comparing control VLPs, CD4-VLPs, and CD4-CCR5-VLPs. The neutralization activity of VLPs was determined in terms of concentrations of the Gag p24 capsid protein. Data points are presented as the mean and SD of duplicate measurements.


cells transfected with CD4 in the absence of Gag had no effect (*SI Appendix, Fig. S4 A and B*).

**CD4-VLPs Neutralize HIV-1 with Enhanced Potency and Breadth Compared with sCD4, CD4-Ig, and a CD4bs bNAb.** To investigate whether CD4 multimerization enhances the potency and breadth of CD4-based inhibitors, the neutralization activity of CD4-VLPs was compared with that of monovalent sCD4, bivalent CD4-Ig, and 3BNC117 IgG, a CD4bs bNAb that has been evaluated in human clinical trials (24, 25). Potency and breadth were compared by quantifying the number of CD4 molecules (CD4-VLPs, sCD4, CD4-Ig) or antigen-binding fragments (Fabs; 3BNC117) required to neutralize a panel of 12 HIV-1 Env reference strains representing the global HIV-1 epidemic (26).

CD4-VLPs neutralized all 12 strains with a geometric mean  $IC_{50}$  of  $1.3 \times 10^8$  VLPs/mL (*SI Appendix, Table S1*). CD4-CCR5-VLPs did not show an overall enhanced potency compared with CD4-VLPs (geometric mean  $IC_{50} = 1.2 \times 10^8$  VLPs/mL). Assuming  $\sim 140$  copies of CD4 per VLP (*SI Appendix, Fig. S2 A–C*), neutralization was achieved at a geometric mean  $IC_{50}$  of  $1.9 \times 10^{10}$  CD4 molecules/mL (Fig. 3A and *SI Appendix, Table S1*). sCD4 and CD4-Ig neutralized only nine (sCD4) or seven (CD4-Ig) of 12 strains with geometric mean  $IC_{50}$  values of 10.0 and 27.7  $\mu\text{g/mL}$ , respectively, equivalent to  $2.3 \times 10^{14}$  and  $3.3 \times 10^{14}$  CD4 molecules/mL (Fig. 3A and *SI Appendix, Table S2*). These results demonstrate that CD4-mediated neutralization of HIV-1 is  $>12,000$ -fold more potent for multivalent CD4, likely due to high-avidity interactions between clustered CD4 receptors and HIV-1 Env.

CD4-VLPs were also more potent and broad than 3BNC117, which neutralized 11 of 12 strains with a geometric mean  $IC_{50}$  of 0.31  $\mu\text{g/mL}$  ( $2.5 \times 10^{12}$  Fabs per mL) (Fig. 3A and *SI Appendix, Table S2*). Thus, the geometric mean  $IC_{50}$  of CD4 molecules on CD4-VLPs was  $>100$ -fold lower than the required concentration of 3BNC117 Fabs and  $>12,000$ -fold lower for the X1632, CH119, and BJOX2000 strains, which are relatively insensitive to 3BNC117. Interestingly, there was only a 15-fold difference between the highest and lowest  $IC_{50}$  values against the 12 strains for CD4-VLPs, compared with a 4,500-fold difference for 3BNC117, highlighting the excellent neutralization breadth of CD4-VLPs.

The neutralization activity of CD4-VLPs was also evaluated against primary isolates obtained from two previously described HIV-1-infected patients (27). These isolates were poorly neutralized by bNAbs targeting various epitopes on Env, including the CD4bs, V1V2, the membrane-proximal external region, and the gp120–gp41 interface ( $IC_{50} > 1 \mu\text{g/mL}$ ) (Fig. 3B and *SI Appendix, Table S3*). However, both isolates were potently neutralized by CD4-VLPs at concentrations similar to  $IC_{50}$  values determined against the HIV-1 strains in the 12-strain panel. Comparing the numbers of CD4 and Fab molecules required for 50% neutralization revealed that CD4-VLPs were 500- to 11,000-fold more potent than the CD4bs bNAb 3BNC117. Similar differences in potency were also observed when comparing CD4-VLPs with bNAbs targeting epitopes other than the CD4bs. These results demonstrate that primary HIV-1 isolates that are resistant to multiple bNAbs can be potently neutralized by a therapeutic that mimics HIV-1 target cells.



**Fig. 3.** CD4-VLPs neutralize HIV-1 with enhanced potency and breadth compared with sCD4, CD4-Ig, and 3BNC117. (A) In vitro neutralization of HIV-1<sub>YU2</sub> and a panel of 12 HIV-1 Env reference strains (26).  $IC_{50}$  values against each strain and the geometric mean  $IC_{50}$  are presented as CD4 copies/mL for CD4-VLPs, sCD4, and CD4-Ig and as Fab copies/mL for 3BNC117 (*SI Appendix, Tables S1 and S2*).  $IC_{50}$  values of 50  $\mu\text{g/mL}$  were used for strains that were not neutralized at 50  $\mu\text{g/mL}$  by sCD4, CD4-Ig, and 3BNC117 for the geometric mean  $IC_{50}$  calculations. (B) In vitro neutralization of two HIV-1 patient isolates that exhibited resistance against multiple bNAbs (27).  $IC_{50}$  values are presented in CD4 copies/mL for CD4-VLPs and in Fab copies/mL for 3BNC117 (CD4bs bNAb), PGDM1400 (V1V2 bNAb), 10E8 (membrane-proximal external region bNAb), and 8ANC195 (gp120–gp41 interface bNAb) (*SI Appendix, Table S3*).



**CD4-CCR5-VLP Treatment in HIV-1-Infected Hu-Mice Elicits CD4bs Mutations in HIV-1 Env Despite Poor Bioavailability.** We investigated the ability of CD4-CCR5-VLPs to suppress HIV-1 replication and prevent viral escape in vivo in HIV-1<sub>YU2</sub>-infected humanized mice (hu-mice). CD4-CCR5-VLPs were selected for in vivo experiments to prevent the potential emergence of CD4-independent HIV-1 escape variants (28–30). To determine an optimal administration regimen, initial half-life studies were performed in uninfected hu-mice. Here,  $7.6 \times 10^9$  CD4-CCR5-VLPs (610 ng of p24) were intraperitoneally (IP) injected into five hu-mice. Blood samples were taken from one animal per time point after 20 min, 1 h, 2 h, 4 h, and 6 h, and plasma CD4-CCR5-VLP concentrations were measured by p24 ELISA. CD4-CCR5-VLP concentrations were either slightly above or slightly below the detection limit of 1.5 ng p24/mL ( $1.9 \times 10^7$  VLPs/mL) at all time points. A peak concentration of  $8.5 \times 10^7$  VLPs/mL was measured at 1 h postinjection. Incomplete diffusion across the peritoneal membrane into the hepatic portal vein and rapid hepatic clearance (31) likely contributed to the poor bioavailability of CD4-CCR5-VLPs administered IP. These studies showed that IP administrations of CD4-CCR5-VLPs reached only subneutralizing plasma concentrations, as peak levels were lower than in vitro neutralization IC<sub>50</sub> values against HIV-1<sub>YU2</sub> (*SI Appendix, Table S1*).

To achieve maximal plasma concentrations for experiments in HIV-1<sub>YU2</sub>-infected mice,  $6 \times 10^9$  control or CD4-CCR5-VLPs were injected IP twice daily for 10 d. This regimen failed to maintain detectable plasma VLP concentrations, as control VLPs and CD4-CCR5-VLPs were undetectable at 6 h postinjection on day 6 of treatment. The efficacy of CD4-CCR5-VLP treatment was compared with that of twice-weekly IP injections of 1 mg of 10–1074, a V3-glycan patch bNAbs currently being evaluated in human clinical trials (32). While 10–1074 treatment achieved robust reductions in viral loads in all treated animals, control and CD4-CCR5-VLPs had no effect on viral loads (Fig. 4A).

To investigate whether intermittent subneutralizing CD4-CCR5-VLP plasma concentrations exert selective pressure on HIV-1 in vivo, the circulating plasma viruses of two HIV-1-infected control VLP-treated animals and three CD4-CCR5-VLP-treated animals were analyzed by single-genome sequencing on day 10 after treatment cessation. Four recurring mutations—G366E, G458D/S, E466K, and G471R—were observed in the gp120 subunits of the HIV-1<sub>YU2</sub> Envs obtained from CD4-CCR5-VLP-treated hu-mice but were rare or absent from sequences derived from control VLP-treated animals (Fig. 4B). All individual mutations occurred in at least two animals and were mutually exclusive, except for one gp120 sequence that contained both G458D and G471R mutations. Together, these variants accounted for 61.5% of the *env* genes sequenced from CD4-CCR5-VLP-treated hu-mice, indicating that these mutations provided a selective advantage in the presence of intermittent subneutralizing CD4-CCR5-VLP plasma concentrations. Interestingly, in one CD4-CCR5-VLP-treated mouse, these mutations were found in 75% of the viruses (*SI Appendix, Fig. S5*).

The substitutions mapped to residues in close proximity to the CD4bs in the gp120 subunit of Env (Fig. 4C), suggesting that the mutations reduced the ability of Env to bind CD4, thereby potentially allowing escape from CD4-based reagents. Indeed, the G366E (33), G458D (34), and G471R (13) mutations have been reported to confer partial resistance against CD4-based inhibitors. No recurrent mutations were found near the coreceptor-binding site, indicating that selective pressure was exerted primarily by CD4 on the CD4-CCR5-VLPs. All mutated residues are highly conserved among HIV-1 Env sequences, whereas the substitutions in the variants are rare (Fig. 4D), suggesting that these mutations could compromise viral fitness.


**HIV-1<sub>YU2</sub> Variants Are Less Infectious and Not Resistant to CD4-VLPs.** Surface plasmon resonance (SPR) studies were performed to determine whether the recurring mutations in *env* sequences from HIV-1-infected and CD4-CCR5-VLP-treated animals affected the CD4-binding affinity of HIV-1<sub>YU2</sub> gp120. Potential avidity effects were avoided by injecting monomeric gp120 proteins (YU2<sub>wt</sub> gp120 and each YU2 gp120 variant) over immobilized CD4-Ig (*SI Appendix, Fig. S6A*). The YU2<sub>G366E</sub> gp120 mutant was excluded from the SPR analysis, as gel electrophoresis showed that this protein was unstable and migrated as multiple species (*SI Appendix, Fig. S6B*).

Changes in CD4 binding were most evident for YU2<sub>G458D</sub> gp120, which dissociated 11-fold faster than YU2<sub>wt</sub> gp120 (Fig. 5A and *SI Appendix, Table S4*). Weaker binding of this mutant was expected, as the Gly in YU2<sub>wt</sub> gp120 directly interacts with CD4, whereas the substituted Asp introduced a negative charge and potential steric clashes at this position (Fig. 4C). Changes in the CD4-binding affinity for the YU2<sub>E466K</sub> and YU2<sub>G471R</sub> gp120 mutants were less pronounced, since residues at both positions do not directly interact with CD4 (Fig. 4C). However, both substitutions introduced positive charges that could destabilize the CD4bs. Although SPR measurements were not possible for YU2<sub>G366E</sub> gp120, the substitution introduces a larger side chain and a negative charge into a residue that directly contacts CD4, and thus it seems likely that YU2<sub>G366E</sub> gp120 binds CD4 more weakly than YU2<sub>wt</sub> gp120.

To ascertain whether the changes in CD4-binding affinity directly impacted the ability of HIV-1 to infect target cells, we performed in vitro infection assays using HIV-1<sub>YU2</sub> pseudoviruses carrying the observed mutations in gp120. Equivalent amounts of p24 (40 pg) were added to target cells for YU2<sub>wt</sub> and the YU2 variant pseudoviruses, and luciferase expression was monitored in CD4<sup>+</sup>/CCR5<sup>+</sup> TZM-bl cells as a measure of HIV-1 infectivity. Infection was greater for the wild-type YU2 virus than for the variants (Fig. 5B); three of the mutant viruses (YU2<sub>G366E</sub>, YU2<sub>E466K</sub>, and YU2<sub>G471R</sub>) were 3.8- to 6.6-fold less infectious than YU2<sub>wt</sub>, while a 24-fold reduction in viral entry fitness was observed for the YU2<sub>G458D</sub> variant. The decreased infectivity of the mutant viruses could be related to changes affecting their binding to CD4, particularly for the YU2<sub>G458D</sub> variant.

In vitro neutralization assays were performed to determine whether the mutations confer resistance to CD4-VLPs and CD4-CCR5-VLPs. All mutant viruses were ~30-fold less sensitive than YU2<sub>wt</sub> to sCD4 and CD4-Ig (Fig. 5C and *SI Appendix, Table S5*). Surprisingly, the mutant viruses were neutralized by CD4-VLPs and CD4-CCR5-VLPs at equivalent concentrations to those required for neutralization of the wild-type virus. This suggests that the mutations provided a selective advantage when exposed to short-lived, subneutralizing concentrations of CD4-CCR5-VLPs but did not decrease viral sensitivity to neutralizing CD4-VLP or CD4-CCR5-VLP concentrations. This demonstrates that CD4bs mutations that enable viral escape against conventional CD4-based inhibitors would not confer resistance to CD4-VLPs.


To investigate whether HIV-1 is able to escape when exposed to neutralizing CD4-VLP concentrations, we performed in vitro evolution experiments. Replication-competent HIV-1<sub>YU2</sub> was propagated on the Rev-A3R5 CD4<sup>+</sup> T cell reporter line (35) for 21 d to generate a diversified viral population. Infection rates were maintained at ~10% of infected cells by transferring the viral supernatant onto fresh target cells every 3 d. To compare the ability of CD4-Ig and CD4-VLPs to suppress viral replication, the viral swarm was distributed into multiple wells and exposed to their respective IC<sub>80</sub>s and IC<sub>95</sub>s for 1 h before fresh target cells were added. This cycle was repeated every 3 d, and a total of six cycles were completed. On day 3, HIV-1-induced GFP expression in Rev-A3R5 cells was measured by flow cytometry, which demonstrated that both inhibitors suppressed infection rates effectively (Fig. 6A). After four cycles (day 12),



**Fig. 4.** CD4-CCR5-VLP treatment in HIV-1<sub>YU2</sub>-infected hu-mice elicits CD4bs mutations in gp120. (A) Viral loads (RNA copies/mL) measured over time (days) in HIV-1<sub>YU2</sub>-infected hu-mice. Each line represents measurements for a single hu-mouse (identified by different numbers). The dotted line indicates the detection limit. Hu-mice were infected 10 d before initiation of treatment: no treatment, twice-daily IP injections of control VLPs ( $6 \times 10^9$  control VLPs per injection), twice-daily IP injections of CD4-CCR5-VLPs ( $6 \times 10^9$  VLPs per injection), or twice-weekly IP injections of the 10-1074 bNAb (1 mg per injection) for 10 d. (B) Pie charts showing the frequency of recurrent mutations in the gp120 subunits of the HIV-1<sub>YU2</sub> env genes of plasma viruses obtained from control VLP-treated and CD4-CCR5-VLP-treated hu-mice. The slices are proportional to the number of sequences containing the indicated substitutions. White slices represent the number of sequences that lacked any recurrent mutations. The numbers in the center indicate the total number of sequences containing recurrent mutations over the total number of sequences analyzed. (C, Left) Cartoon diagram of Env trimer structure (Protein Data Bank ID code 5T3Z), with locations of residues that were mutated highlighted as colored surfaces. (C, Right) Close-up view of the gp120-CD4 binding interface highlighting the proximity of the mutated residues to the CD4bs. (D) Levels of conservation of each mutated residue and its respective substitution (<https://www.hiv.lanl.gov/>).

infection rates increased to >4% in the presence of 17.5  $\mu$ g/mL CD4-Ig (IC<sub>80</sub>) for all replicates, which was set as a threshold to indicate viral escape. CD4-Ig concentrations were doubled to

35  $\mu$ g/mL for the next cycle to assess whether the viral swarms were still sensitive to higher inhibitor concentrations. No signs of viral escape were observed for all other conditions at this point.



**Fig. 5.** HIV-1<sub>YU2</sub> variants have lower affinity for CD4, are less infectious, and are not resistant to CD4-VLPs. (A) SPR-binding assays of CD4-Ig with YU2<sub>WT</sub> and YU2 variant gp120 proteins. Representative sensograms (red) and fits (black) for binding of YU2<sub>WT</sub>, YU2<sub>G458D</sub>, YU2<sub>E466K</sub>, and YU2<sub>G471R</sub> gp120 proteins to CD4-Ig captured on a protein A biosensor chip (*SI Appendix, Fig. S6A*). The YU2<sub>G366E</sub> gp120 mutant was excluded from the SPR analysis, as this protein was unstable (*SI Appendix, Fig. S6B*). YU2 gp120 proteins were flowed over the chip as a fourfold dilution series with a maximum concentration of 250 nM.  $K_D$ ,  $k_a$ , and  $k_d$  values are presented in *SI Appendix, Table S4*. (B) Infectivity assay comparing the ability of WT and variant HIV-1<sub>YU2</sub> pseudoviruses to enter and infect target cells. YU2<sub>WT</sub> or mutant viruses (40 pg p24) were added to TZM-bl cells, and luminescence was measured after 48 h. Columns and error bars represent the mean and SDs for measurements from three separate experiments using eight replicates per experiment. (C) Overlay of neutralization curves for CD4-VLPs, sCD4, and CD4-Ig against YU2<sub>WT</sub> and the indicated YU2 mutant pseudoviruses. Inhibitor concentrations are shown as p24 concentrations for CD4-VLPs (Fig. 2C and *Methods*) and protein concentrations for sCD4 and CD4-Ig. Data points are presented as the mean and SD of duplicate measurements. IC<sub>50</sub> values for CD4-VLPs, CD4-CCR5-VLPs, sCD4, and CD4-Ig against YU2<sub>WT</sub> and YU2 mutant pseudoviruses are presented in *SI Appendix, Table S5*.

After cycles 5 and 6 (days 15 and 18), infection rates also increased in the presence of 22.5 μg/mL CD4-Ig (IC<sub>95</sub>), and viral escape was observed for two of three replicates (Fig. 6A). Interestingly, infection rates for CD4-Ig (IC<sub>80</sub>) remained above 4% for two of three replicates even after the concentration was increased to 70 μg/mL after the fifth cycle. Infection rates remained low for CD4-VLPs at both concentrations, suggesting that a therapeutic that presents clusters of CD4 is more effective than traditional CD4-based inhibitors in controlling HIV-1 replication and preventing viral escape.


A modified version of a recently published in vitro evolution protocol (36) was used to evaluate whether HIV-1 can escape when intermittently exposed to increasing CD4-VLP concentrations. As above, the diversified HIV-1<sub>YU2</sub> swarm was exposed to CD4-Ig and CD4-VLPs at starting concentrations of 17.5 μg/mL and 5 × 10<sup>8</sup> VLPs/mL, respectively, for 1 h, followed by the addition of fresh target cells. After 3 d, infection rates were assessed under a fluorescent microscope, and the cycle was repeated in the absence of inhibitor to enable HIV-1 replication and ensure sufficient viral titers for the next selection cycle. This 6-d on/off cycle was repeated 15 times (90 d), and inhibitor concentrations were gradually increased to final concentrations of 280 μg/mL of CD4-Ig and 1.6 × 10<sup>10</sup> CD4-VLPs/mL. To evaluate whether the selected viral swarms were resistant to the inhibitors, in vitro neutralization assays were performed. The diversified HIV-1<sub>YU2</sub> control swarm that was continuously passaged in the absence of any inhibitor remained as sensitive as YU2<sub>WT</sub> to CD4-Ig (IC<sub>50</sub> = 0.91 μg/mL) and CD4-VLPs (IC<sub>50</sub> =

0.02 μg p24/mL) (Fig. 6B); however, the HIV-1<sub>YU2</sub> swarm that was intermittently exposed to increasing CD4-Ig concentrations was completely resistant to CD4-Ig (IC<sub>50</sub> >100 μg/mL). In contrast, the viral swarm that was passaged in the presence of CD4-VLPs remained as sensitive to CD4-VLPs as the control swarm (IC<sub>50</sub> = 0.014 μg p24/mL) (Fig. 6B). Importantly, CD4-VLPs also potentially neutralized the CD4-Ig-resistant swarm (IC<sub>50</sub> = 0.009 μg p24/mL), confirming that escape pathways against conventional CD4-based inhibitors are ineffective against CD4-VLPs. These results demonstrate that decoy therapeutics designed to present clusters of CD4 have the potential to effectively control HIV-1 replication and prevent viral escape.

## Discussion

Here we show that virus-like nanoparticles that mimic HIV-1 target cells by presenting an array of CD4 molecules neutralize HIV-1 with enhanced potency and breadth compared with conventional CD4-based inhibitors and bNAbs. In vivo studies in HIV-1<sub>YU2</sub>-infected hu-mice showed that intermittent sub-neutralizing CD4-CCR5-VLP plasma concentrations induced recurring CD4bs mutations in Env that reduced viral fitness and neutralization sensitivity to sCD4 and CD4-Ig in vitro, but all mutant viruses remained as sensitive as wild-type virus to CD4-VLPs at neutralizing concentrations. In vitro evolution studies demonstrated that CD4-VLPs effectively controlled HIV-1 replication, and viral escape was not observed. These results provide an explanation for the lack of efficacy of conventional CD4-based inhibitors and motivate the development of therapeutic





**Fig. 6.** CD4-VLPs suppress HIV-1 replication and prevent viral escape in vitro. (A) In vitro evolution experiment comparing the ability of CD4-Ig and CD4-VLPs to suppress HIV-1 replication. Before the experiment, a diversified viral swarm had been generated by passaging replication-competent HIV-1<sub>YU2</sub> on Rev-A3R5 CD4<sup>+</sup> T cells for 21 d. On day 0, the viral supernatant was distributed into multiple wells, and IC<sub>50</sub> (red) and IC<sub>95</sub> (blue) concentrations of CD4-Ig (Top) or CD4-VLPs (Bottom) were added. After 1 h, fresh Rev-A3R5 cells were added, and infection rates were determined by measuring HIV-1-induced GFP expression by flow cytometry after 72 h. This cycle was repeated every 3 d, and a total of six cycles were completed. An infection rate >4% was set as a threshold to indicate viral escape (dashed line), and inhibitor concentrations were doubled (\*) for replicates that surpassed this threshold for the next cycle. (B) In vitro neutralization assays for CD4-Ig (Top) and CD4-VLPs (Bottom) against HIV-1<sub>YU2</sub> swarms that had been extensively passaged in the presence of no inhibitor (red), CD4-Ig (blue), or CD4-VLPs (green) (Methods). Inhibitor concentrations are shown as protein concentrations for CD4-Ig and as p24 concentrations for CD4-VLPs (Fig. 2C and Methods). Data points are presented as the mean  $\pm$  SD of duplicate measurements.

strategies that more accurately mimic HIV-1 target cells to prevent viral escape and provide sustained suppression of HIV-1.

The enhanced neutralization potency and breadth of CD4-VLPs implies that membrane-associated display of multiple CD4 molecules is a more accurate mimic of the HIV-1 target cell compared with monovalent or bivalent CD4-based inhibitors. Cell surface CD4 receptors colocalize in nanoclusters that contain ~4 to 15 molecules of CD4 (37, 38), which would facilitate multivalent binding to HIV-1 Envs. Because Env spikes are trimeric, each Env can bind up to three CD4 receptors, and multiple Envs may be engaged during the cell entry process (39, 40), leading to avidity effects. Compared with soluble CD4-based therapeutics, such as sCD4 and CD4-Ig, CD4-VLPs required >12,000-fold fewer copies of CD4 to neutralize a diverse panel of HIV-1 strains. This suggests that multiple CD4-Env interactions between CD4-VLPs and HIV-1 virions were formed, making it nearly impossible for HIV-1 to dissociate from CD4-VLPs and thereby minimizing the number of VLPs required to neutralize HIV-1. Cryo-ET imaging of CD4-VLPs is consistent with the involvement of distinct CD4 nanoclusters on a single VLP in neutralizing multiple virions simultaneously. Moreover, a single HIV-1 virion could be completely neutralized by two to four CD4-VLPs, as bound VLPs would

sterically hinder the virus from interacting with target cells. The relatively large sizes of CD4-VLPs likely also prevented the enhancement of HIV-1 infection of target cells in vitro, which has been observed for sCD4 at low concentrations (41).

Twice-daily IP injections of large doses of CD4-CCR5-VLPs produced only intermittent subneutralizing plasma concentrations in hu-mice, likely due to rapid clearance by hepatic sinusoidal endothelial cells, which have been shown to clear nanoparticles at a rate of up to  $10^8$  particles/min (31). As for conventional CD4-based inhibitors, interactions with class II major histocompatibility complex (MHC) proteins presented on antigen-presenting cells could shorten the half-life of CD4-CCR5-VLPs. Although human antigen-presenting cells have been shown to be generated in the hu-mouse model used in this study (42, 43), the bioavailabilities of control VLPs and CD4-CCR5-VLPs were similarly poor, suggesting that low VLP concentrations were not related to binding to human class II MHC-expressing cells. Despite poor bioavailability, intermittent subneutralizing CD4-CCR5-VLP concentrations elicited recurrent mutations in the CD4bs in circulating viruses. In vitro neutralization assays showed that YU2 viruses with these mutations were as sensitive to CD4-VLPs and CD4-CCR5-VLPs as the wild-type YU2 virus. We postulate that the mutations provided an advantage in the presence of short-lived subneutralizing CD4-CCR5-VLP concentrations, but did not confer resistance to neutralizing concentrations of CD4-VLPs and CD4-CCR5-VLPs. It is possible that the mutations protected the virus during short periods immediately after injections when there were relatively high plasma CD4-CCR5-VLP concentrations and/or protected the virus against constant exposure to low CD4-CCR5-VLP concentrations. In contrast, all mutant viruses were 30-fold less sensitive to sCD4 and CD4-Ig. For three of the four mutations, this loss of neutralization sensitivity was accompanied by only a fourfold to sevenfold reduction in infectivity. These results confirm that the ability of Env to bind multiple CD4 receptors on the target cell with avidity provides an escape route for HIV-1 against sCD4 and CD4-Ig, as the virus is able to tolerate CD4bs mutations that lower the intrinsic binding affinity for monomeric sCD4 or bivalent CD4-Ig without considerable fitness cost.

Our in vitro evolution experiments show that CD4-VLPs effectively suppressed viral replication at neutralizing concentrations, and that intermittent exposure to increasing CD4-VLP concentrations failed to select resistant viral swarms. This evolution strategy has been shown to generate viral populations completely resistant to CD4-Ig and the CD4bs bNAb NIH45-46 (36). A modest loss in viral sensitivity was also observed for the potent antibody-like inhibitor eCD4-Ig, a fusion of CD4-Ig and a CCR5-mimetic sulfopeptide that protected rhesus macaques from simian-HIV challenge following delivery using an adeno-associated virus vector (44). Similar to eCD4-Ig, viral swarms resistant to CD4-Ig remained sensitive to CD4-VLPs, demonstrating that escape pathways that are effective against conventional CD4-based inhibitors do not enable HIV-1 to escape against therapeutics that more accurately mimic HIV-1 target cells. Overall, our results suggest that effective viral escape against CD4-VLPs is difficult as the neutralization sensitivity to the therapeutic and the ability to infect target cells decrease concomitantly, thus forcing HIV-1 to become progressively less infectious.

CD4-VLPs were >100-fold more potent against a globally representative virus panel than the CD4bs bNAb 3BNC117 when comparing the required numbers of CD4 molecules vs. IgG Fabs. Importantly, CD4-VLPs were >12,000-fold more potent against three viral strains that were poorly neutralized by 3BNC117 and also potentially neutralized two clinical viral isolates that were partially or completely resistant to 3BNC117 and other bNAbs. Therapeutics that present multiple copies of CD4 tethered to a surface have two potential advantages over bNAbs that could

promote greater neutralization breadth and resistance to viral escape: (i) anti-Env IgGs (and CD4-Ig) are unlikely to use avidity effects to bind HIV-1 Env, because the low spike density on the viral surface and the distribution of epitopes on the Env trimer result in primarily monovalent binding that is vulnerable to escape through mutation of HIV-1 Env (16, 17); and (ii) although HIV-1 can mutate to become resistant to any single antibody (5), it must retain the ability to interact with its receptor to infect cells.

In summary, our results demonstrate that nanoparticles that mimic HIV-1 target cells by presenting multiple copies of membrane-associated CD4 neutralize HIV-1 with enhanced potency, breadth, and resistance to viral escape compared with conventional CD4-based inhibitors and CD4bs bNAbs. Therefore, we postulate that therapeutics that mimic viral target cells could prevent escape and permanently control HIV-1 infection by exposing a universal vulnerability—the requirement to bind clusters of CD4 on a target cell—that is potentially inherent to all HIV-1 strains and variants. Since direct injections of CD4-VLPs failed to achieve therapeutic concentrations in vivo, alternative therapeutic and/or delivery strategies that ensure durable bioavailability and minimize the requirement for repeated administrations need to be developed to translate this concept into a clinically feasible functional cure therapy.

## Materials and Methods

**VLP Production.** VLPs were produced by transiently transfecting Expi293 cells (Life Technologies) grown in Expi293 expression media (Life Technologies) on an orbital shaker at 37 °C and 8% CO<sub>2</sub>. Cells were transfected with a plasmid vector expressing Rev-independent HIV-1 Gag-Pol (pHDM-Hgpm2 plasmid; PlasmID Repository, Harvard Medical School) or a Gag-EGFP fusion protein (HIV-1 HXB2 Gag-EGFP expression vector; NIH AIDS Reagent Program). To generate CD4-VLPs and CD4-CCR5-VLPs, cells were cotransfected with a second plasmid (cDNA sequences of CD4 and CCR5 subcloned into the pHAGE-CMV-IRES-ZsGreen plasmid; PlasmID Repository, Harvard Medical School) encoding CD4 alone or CD4 and CCR5 at a DNA ratio of 4:1 Gag-Pol:CD4 (CCR5). Control VLPs were generated by expression of HIV-1 Gag-Pol alone. Expi293 cells were also transfected with CD4 in the absence of Gag-Pol to make CD4<sup>+</sup> extracellular vesicles. At 48 to 72 h posttransfection, cells were centrifuged at 350 × g for 8 min, and supernatants were collected and passed through a 0.45-μm syringe filter.

**VLP Purification.** For in vitro neutralization experiments, VLPs were concentrated and buffer-exchanged into T2M-bl cell culture medium in Amicon Ultra-15 centrifugal filter units with a 100-kDa molecular weight cutoff (Millipore). For initial experiments, VLPs were isolated by ultracentrifugation at 28,000 rpm (96,000 × g) for 2 h at 4 °C using a SW32 Ti rotor and a Beckman L8-80M ultracentrifuge (Beckman Coulter) on a 20% wt/vol sucrose cushion. The supernatant was carefully aspirated, and the pellet was resuspended in 500 μL of culture medium at 4 °C overnight.

For quantitative Western blot analysis and cryo-ET imaging studies, 50 mL of filtered supernatant (combined from five independent CD4-VLP productions) was concentrated and buffer-exchanged into 500 μL of PBS by sucrose cushion ultracentrifugation as described above, centrifuged at 10,000 × g for 15 min, passed through a 0.45-μm syringe filter, and further purified by size exclusion chromatography on a Superose 6 10/300 column (GE Healthcare) equilibrated with 20 mM NaHPO<sub>4</sub> (pH 7.4) and 150 mM NaCl. Fractions were collected and loaded onto 4 to 20% polyacrylamide gels (Bio-Rad) and stained with InstantBlue protein stain (Expedeon).

For in vivo experiments, control and CD4-CCR5-VLPs were concentrated from 1,000 mL to 5 mL in Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific) that were immersed in a 40% wt/vol PEG (20 kDa) in ultrapure water concentrating solution (Thermo Fisher Scientific) and then buffer-exchanged into PBS.

**VLP Quantification.** VLP concentrations were quantified using a lentivirus-associated p24 ELISA kit (Cell Biolabs). To ensure accurate quantification of VLPs for in vitro neutralization studies, we used Gag-Pol instead of Gag-EGFP for generating VLPs, because detection of the Gag-encoded capsid protein p24 is less efficient for immature Gag than for mature Gag that had been processed by the HIV-1 protease encoded within Pol after budding (45). VLP concentrations were calculated using the following equation in accordance

with the manufacturer's directions: 1 ng p24 = 1.25 × 10<sup>7</sup> VLPs (46, 47), which assumes that each VLP contains 2,000 molecules of p24 (20, 21).

**In Vitro Neutralization Assays.** The ability of VLPs to neutralize HIV-1 was evaluated using a pseudovirus-based TZM-bl assay (22). Pseudoviruses with Envs from YU2<sub>wt</sub>, YU variants, and strains from a 12-strain global HIV-1 panel (26) were generated in HEK293T cells as described previously (48). Serial dilutions of control VLPs, CD4-VLPs, and CD4-CCR5-VLPs were incubated with pseudovirus for 1 h at 37 °C. TZM-bl cells (NIH AIDS Reagents Program) that express a Tat-inducible luciferase reporter gene were added, and luminescence was measured after 48 h. The HIV-1 neutralization activity of CD4-VLPs was compared with that of sCD4, CD4-Ig, and the CD4bs bNAb 3BNC117. Neutralization assays were also performed against primary virus isolates obtained from the latent reservoirs of two HIV-1-infected patients who received repeated infusions of 3BNC117 (27). Viruses were isolated from peripheral blood mononuclear cells by a quantitative and qualitative viral outgrowth assay (Q<sup>2</sup>VOA) as described previously (49).

The number of CD4 molecules/mL required to achieve 50% neutralization was calculated by multiplying the VLP concentration (derived from the p24 ELISA) at the IC<sub>50</sub> (derived from an in vitro neutralization assay) by the average number of CD4 copies per VLP (derived from quantitative Western blot analysis). For sCD4 D1D2 (26 kDa), CD4-Ig (100 kDa), and 3BNC117 (150 kDa), the numbers of CD4 molecules/mL (sCD4, CD4-Ig) or Fab molecules/mL (3BNC117) were calculated by converting the measured IC<sub>50</sub> values (in μg/mL) to molar concentrations. The respective numbers of inhibitor molecules were then derived from molar IC<sub>50</sub> concentrations using Avogadro's number. The numbers of inhibitor molecules (CD4 or Fab) were then multiplied by a factor of one (sCD4) or two (CD4-Ig, 3BNC117), depending on whether the inhibitor molecule contained one or two CD4/Fab copies. IC<sub>50</sub> values calculated from independent assays generally agreed to within twofold to fourfold (SI Appendix, Fig. S3).

**In Vivo Studies.** Studies in hu-mice were performed in accordance with the recommendations in the NIH's *Guide for the Care and Use of Laboratory Animals*. The protocol was reviewed and approved by The Rockefeller University's Institutional Animal Care and Use Committee, and experiments were designed in accordance with established guidelines at The Rockefeller University (protocol no. 13618-H).

Hu-mice were generated as described previously (50). In brief, human CD34<sup>+</sup> hematopoietic stem cells were obtained from human fetal livers (Human Fetal Tissue Repository) and injected intrahepatically into irradiated nonobese diabetic Rag1<sup>-/-</sup> IL2rg<sup>null</sup> (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ) mice (The Jackson Laboratory). Half-life studies for VLPs were performed in uninfected hu-mice. CD4-CCR5-VLPs (610 ng of p24) were injected IP into five hu-mice, and a single blood sample was taken from each animal after 20 min, 1 h, 2 h, 4 h, or 6 h. Plasma CD4-CCR5-VLP concentrations were measured by lentivirus-associated p24 ELISA (Cell Biolabs).

For treatment experiments, hu-mice were infected with HIV-1<sub>YU2</sub>, and viral plasma loads were measured by qRT-PCR at 10 d postinfection as described previously (50). Infected hu-mice were distributed into four treatment groups: no treatment (group I), twice-daily IP injections of 480 ng p24 of control VLPs (group II) or CD4-CCR5-VLPs (group III), or twice-weekly administration of 1 mg of the bNAb 10-1074 (group IV). Treatments were continued for a total of 10 d, and viral plasma loads were measured on days 3, 6, and 10 by qRT-PCR as described previously (50).

**Viral Fitness Assay.** To evaluate the ability of HIV-1<sub>YU2</sub> Env mutants to enter and infect target cells, a previously described infection assay (51, 52) was used with minor modifications. Here 40 pg p24 of YU2<sub>wt</sub> or mutant YU2 pseudoviruses (quantified by lentivirus-associated p24 ELISA; Cell Biolabs) were added to TZM-bl reporter cells in the presence of 30 μg/mL DEAE-dextran. After a 48-h incubation at 37 °C, cells were lysed, and luminescence was measured after the addition of britelite plus (PerkinElmer). The average luminescence among eight 8 replicates was calculated for YU2<sub>wt</sub> and each YU2 variant, and the experiment was repeated three times with different pseudovirus batches. The viral entry fitness of the YU2 mutant viruses was calculated as a function of the reduction in average luminescence compared with YU2<sub>wt</sub>.

**In Vitro Evolution Assays.** Replication-competent HIV-1<sub>NL4-3</sub> carrying the HIV-1<sub>YU2</sub> envelope (53) was passaged on Rev-A3R5 CD4<sup>+</sup> T cells (35) (Cube Bio-Systems) for 21 d to diversify the viral population. Rev-A3R5 cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 1% pen-strep, 1% L-glutamine, 1 mg/mL geneticin, and 1 μg/mL puromycin at 37 °C and 5% CO<sub>2</sub>. To test whether CD4-VLPs can suppress viral replication, 30 μL



of viral supernatant was added to multiple wells on a 48-well plate. Previously determined  $IC_{50}$ s and  $IC_{95}$ s of CD4-Ig (17.5 and 22.5  $\mu$ g/mL) and CD4-VLPs ( $5 \times 10^8$  and  $1.25 \times 10^9$  VLPs/mL) or no inhibitor were added to the wells in triplicate in the presence of 5  $\mu$ g/mL DEAE-dextran, and then media was added for a final volume of 500  $\mu$ L. After 1 h of incubation at 37 °C,  $5 \times 10^4$  Rev-A3R5 cells were added, and the plates were incubated for 16 h at 37 °C. The next day, cells were centrifuged at  $350 \times g$  for 8 min, supernatants were removed, and cells were resuspended in 500  $\mu$ L of fresh medium. After 48 h, infection rates were quantified by measuring HIV-1-induced GFP expression in Rev-A3R5 cells by flow cytometry (MACSQuant; Miltenyi Biotec). For the second cycle, 350  $\mu$ L of viral supernatants for each condition were transferred into fresh 48-well plates and inhibitors, DEAE-dextran, and cells were added as in cycle 1. A total of six cycles were performed, and infection rates were determined after cycles 4 to 6. Infection rates in the absence of inhibitor were maintained at  $\sim 10\%$  infected cells, and to account for variations between cycles, infection rates were normalized to a viral control infection of 10%. Viral escape was defined as  $>4\%$  infected cells (60% neutralization), and inhibitor concentrations were increased twofold for replicates that surpassed this threshold for the next cycle.

A modified version of a previously described in vitro evolution protocol (36) was used to evaluate whether HIV-1 can escape from CD4-VLPs when intermittently exposed to increasing inhibitor concentrations. Here 10 to 20  $\mu$ L of viral supernatant was added to multiple wells on a 96-well plate, then CD4-Ig and CD4-VLPs were added at starting concentrations of 17.5  $\mu$ g/mL and  $5 \times 10^8$  VLPs/mL, respectively, in the presence of 5  $\mu$ g/mL DEAE-dextran, and finally medium was added for a final volume of 200  $\mu$ L. After a 1-h incubation at 37 °C,  $2.5 \times 10^4$  cells were added, and the plates were incubated at 37 °C. After 8 h, cells were centrifuged, supernatants were removed, and cells were resuspended in 200  $\mu$ L of fresh medium. After 64 h, infection rates were assessed using a fluorescent microscope (Zeiss AX10). The second cycle was performed in the absence of inhibitor to enable HIV-1

replication and ensure sufficient viral titers for the next selection cycle. This 6-d on/off cycle was repeated 15 times (90 d), and inhibitor concentrations were doubled every two to four cycles to final concentrations of 280  $\mu$ g/mL of CD4-Ig and  $1.6 \times 10^{10}$  CD4-VLPs/mL. To maintain infections at higher inhibitor concentrations, up to 150  $\mu$ L of viral supernatant was passaged, and repeated cycles in the absence of inhibitor were performed. After the final cycle, viral supernatants for each condition (no inhibitor, CD4-Ig, and CD4-VLPs) were collected and TZMbl assays were performed as described above.

**Statistical Analysis.** Concentrations at which half-maximal neutralization was observed ( $IC_{50}$  values) were calculated using software in the HIV Antibody Database (54). The levels of conservation of the mutated residues and the respective substitutions observed in *env* sequences obtained from HIV-1-infected and CD4-CCR5-VLP-treated hu-mice were determined through filtered web alignment of HIV-1 sequences in the Los Alamos National Laboratory HIV Database (<https://www.hiv.lanl.gov/>).

**Data and Materials Availability.** All data associated with this study are available in the main text or *SI Appendix*.

**ACKNOWLEDGMENTS.** We thank the Caltech Protein Expression Center in the Beckman Institute, Y. E. Lee, and T. Luong for expression of VLPs and proteins; J. R. Keeffe for reagents; M. G. Murphy for help with figures; C. Kieffer and A. P. West for helpful discussion and advice; J. C. C. Lorenzi for primary viral isolates; T. Eisenreich and L. Nogueira for help with mouse experiments; J. A. Pai for bioinformatic analyses; and the NIH AIDS Reagent Program for reagents. Cryo-ET was performed in the Beckman Institute Resource Center for Transmission Electron Microscopy at Caltech. This work was supported by the Bill and Melinda Gates Foundation (Grant OPP1202246) and by a generous gift from Kairos Ventures.

1. S. K. Choudhary, D. M. Margolis, Curing HIV: Pharmacologic approaches to target HIV-1 latency. *Annu. Rev. Pharmacol. Toxicol.* **51**, 397–418 (2011).
2. T. Bruehl, O. Schwartz, Markers of the HIV-1 reservoir: Facts and controversies. *Curr. Opin. HIV AIDS* **13**, 383–388 (2018).
3. R. F. Siliciano, W. C. Greene, HIV latency. *Cold Spring Harb. Perspect. Med.* **1**, a007096 (2011).
4. C. Katlama *et al.*, Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. *Lancet* **381**, 2109–2117 (2013).
5. M. R. Gardner, M. Farzan, Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. *Curr. Opin. HIV AIDS* **12**, 294–301 (2017).
6. A. Falkenhagen, S. Joshi, Further characterization of the bifunctional HIV entry inhibitor sCD4-Flt45. *Mol. Ther. Nucleic Acids* **7**, 387–395 (2017).
7. S. C. Harrison, Viral membrane fusion. *Virology* **479–480**, 498–507 (2015).
8. R. T. Schooley *et al.*, Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. *Ann. Intern. Med.* **112**, 247–253 (1990).
9. T. Schacker *et al.*, Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* **9**, 145–152 (1995).
10. E. S. Daar, X. L. Li, T. Moudgil, D. D. Ho, High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. *Proc. Natl. Acad. Sci. U.S.A.* **87**, 6574–6578 (1990).
11. P. J. Klasse, J. A. McKeating, Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: A phenotypic characterization. *AIDS Res. Hum. Retroviruses* **9**, 595–604 (1993).
12. J. A. McKeating *et al.*, Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. *J. Virol.* **67**, 5216–5225 (1993).
13. K. Gruppung *et al.*, MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. *Retrovirology* **9**, 36 (2012).
14. J. Arthos *et al.*, Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: Implications for therapeutic and vaccine strategies. *J. Biol. Chem.* **277**, 11456–11464 (2002).
15. A. Trautnecker, J. Schneider, H. Kiefer, K. Karjalainen, Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. *Nature* **339**, 68–70 (1989).
16. J. S. Klein, P. J. Bjorkman, Few and far between: How HIV may be evading antibody avidity. *PLoS Pathog.* **6**, e1000908 (2010).
17. R. P. Galimidi *et al.*, Intra-spike crosslinking overcomes antibody evasion by HIV-1. *Cell* **160**, 433–446 (2015).
18. A. Amitai, A. K. Chakraborty, M. Kardar, The low spike density of HIV may have evolved because of the effects of T helper cell depletion on affinity maturation. *PLoS Comput. Biol.* **14**, e1006408 (2018).
19. D. Gheysen *et al.*, Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. *Cell* **59**, 103–112 (1989).
20. L. A. Carlson *et al.*, Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. *Cell Host Microbe* **4**, 592–599 (2008).
21. N. L. Goicochea *et al.*, Structure and stoichiometry of template-directed recombinant HIV-1 Gag particles. *J. Mol. Biol.* **410**, 667–680 (2011).
22. D. C. Montefiori, "Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays" in *Curr. Protoc. Immunol.*, (2005), Vol. Chapter 12, p. Unit 12.11.
23. M. Tkach, C. Théry, Communication by extracellular vesicles: Where we are and where we need to go. *Cell* **164**, 1226–1232 (2016).
24. M. Caskey *et al.*, Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature* **522**, 487–491 (2015).
25. P. Mendoza *et al.*, Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature* **561**, 479–484 (2018).
26. A. deCamp *et al.*, Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. *J. Virol.* **88**, 2489–2507 (2014).
27. Y. Z. Cohen *et al.*, Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. *J. Exp. Med.* **215**, 2311–2324 (2018).
28. P. Kolchinsky *et al.*, Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. *J. Virol.* **73**, 8120–8126 (1999).
29. P. R. Gorry *et al.*, Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. *J. Virol.* **76**, 6277–6292 (2002).
30. A. Laurén, E. Vincic, H. Hoshino, R. Thorstensson, E. M. Fenyő, CD4-independent use of the CCR5 receptor by sequential primary SIVm isolates. *Retrovirology* **4**, 50 (2007).
31. J. M. Mates *et al.*, Mouse liver sinusoidal endothelium eliminates HIV-like particles from blood at a rate of 100 million per minute by a second-order kinetic process. *Front. Immunol.* **8**, 35 (2017).
32. M. Caskey *et al.*, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nat. Med.* **23**, 185–191 (2017).
33. H. Dreja, C. Pade, L. Chen, Á. McKnight, CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. *J. Gen. Virol.* **96**, 1899–1905 (2015).
34. R. M. Lynch *et al.*, HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. *J. Virol.* **89**, 4201–4213 (2015).
35. R. J. McLinden *et al.*, Detection of HIV-1 neutralizing antibodies in a human CD4<sup>+</sup>/CXCR4<sup>+</sup>/CCR5<sup>+</sup> T-lymphoblastoid cell assay system. *PLoS One* **8**, e77756 (2013).
36. C. H. Fellingner *et al.*, eCD4-Ig limits HIV-1 escape more effectively than CD4-Ig or a broadly neutralizing antibody. *J. Virol.* **93**, e00443-19 (2019).
37. K. H. Roh, B. F. Lillemeier, F. Wang, M. M. Davis, The coreceptor CD4 is expressed in distinct nanoclusters and does not colocalize with T-cell receptor and active protein tyrosine kinase p56lck. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E1604–E1613 (2015).
38. I. I. Singer *et al.*, CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. *J. Virol.* **75**, 3779–3790 (2001).
39. R. Sougrat *et al.*, Electron tomography of the contact between T cells and SIV/HIV-1: Implications for viral entry. *PLoS Pathog.* **3**, e63 (2007).
40. J. Chojnacki *et al.*, Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. *Science* **338**, 524–528 (2012).
41. N. Sullivan *et al.*, Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. *J. Virol.* **72**, 6332–6338 (1998).

42. F. Ishikawa *et al.*, Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. *Blood* **106**, 1565–1573 (2005).
43. Y. Saito, J. M. Ellegast, M. G. Manz, Generation of humanized mice for analysis of human dendritic cells. *Methods Mol. Biol.* **1423**, 309–320 (2016).
44. M. R. Gardner *et al.*, AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. *Nature* **519**, 87–91 (2015).
45. J. Hammonds *et al.*, Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. *Virology* **314**, 636–649 (2003).
46. J. S. Gach *et al.*, Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. *PLoS Pathog.* **13**, e1006793 (2017).
47. C. A. Vink *et al.*, Eliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy. *Mol. Ther.* **25**, 1790–1804 (2017).
48. R. Diskin *et al.*, Increasing the potency and breadth of an HIV antibody by using structure-based rational design. *Science* **334**, 1289–1293 (2011).
49. J. C. Lorenzi *et al.*, Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E7908–E7916 (2016).
50. F. Klein *et al.*, HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature* **492**, 118–122 (2012).
51. O. F. Brandenberg *et al.*, Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. *Retrovirology* **11**, 75 (2014).
52. H. Li *et al.*, Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E3413–E3422 (2016).
53. Y. J. Zhang *et al.*, Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. *J. Virol.* **76**, 6332–6343 (2002).
54. A. P. West Jr. *et al.*, Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 10598–10603 (2013).